首页> 外文期刊>Disease Management >Concurrent Use of Opioids with Other Central Nervous System-Active Medications Among Older Adults
【24h】

Concurrent Use of Opioids with Other Central Nervous System-Active Medications Among Older Adults

机译:同时使用阿片类药物与其他中枢神经系统活性药物在老年人中

获取原文
获取原文并翻译 | 示例
           

摘要

The primary objective was to determine the prevalence and characteristics of older adults concurrently using opioids and other central nervous system (CNS)-active medications, and the specialties of providers who ordered the medications. A secondary objective was to document medication-related adverse effects associated with such concurrent drug use. Study populations were identified as older adults aged = 65 years with 1 year continuous medical and drug plan enrollment during 2017 and opioid use of = 2 prescriptions for = 15 days' supply. CNS-active medications included benzodiazepines, non-benzodiazepine hypnotics, muscle relaxants, antipsychotics, and gabapentinoids. Provider specialties were identified from the National Provider Identification database. Characteristics associated with opioids only, opioids plus 1, and opioids plus = 2 additional CNS-active medications were determined using multinomial logistic regression. Outcome measures during 2017 included injurious falls/fractures and = 3 emergency room (ER) visits. Among eligible insureds (N = 209,947), 57% used opioids only, 28% used opioids plus 1 additional CNS medication, and 15% used = 2 additional medications. About 60% of opioids and other concurrent CNS medications were prescribed by the same provider, generally a primary care provider. Benzodiazepines and gabapentinoids were most often used concurrently with opioids. Health status, insomnia, anxiety, depression, and low back pain had the strongest associations with concurrent medication use. Overall, concurrent use with = 2 CNS medications increased the likelihood of injurious falls/fractures or = 3 ER visits in this population by about 18% and 21%, respectively. Both patients and providers may benefit from an awareness of adverse outcomes associated with concurrent opioid and other CNS-active medication use.
机译:主要目的是使用阿片类药物和其他中枢神经系统(CNS) - 治疗药物和订购药物的提供者的专业来确定老年人的患病率和特征。次要目标是记录与这种并发药物使用相关的药物相关的不利影响。研究人群被鉴定为年龄> = 65岁的老年人,2017年持续的1年持续的医疗和药物计划入学和阿片类药物使用> = 2个处方的供应。 CNS-活跃的药物包括苯二氮卓,非苯并二氧基催眠药,肌肉松弛剂,抗精神病药和甘蓝产蛋白。从国家提供商识别数据库中确定提供商专业。仅使用多项逻辑回归测定与阿片类药物的特性,阿片类药物加1和阿片类药物和阿片类药物= 2额外的CNS活跃的药物。 2017年期间的结果措施包括有害跌落/骨折和> = 3急诊室(ER)访问。在符合条件的投保(n = 209,947)中,仅使用57%的阿片类药物,28%使用阿片类药物加上1个额外的CNS药物,15%使用> = 2种另外的药物。大约60%的阿片类药物和其他并发CNS药物由同一提供者规定,通常是初级保健提供者。苯二氮卓和甘蓝产脂蛋白最常与阿片类药物同时使用。健康状况,失眠,焦虑,抑郁和低腰疼痛具有最强的关联,并使用并发用药。总体而言,同时使用> = 2个CNS药物增加了有害的跌落/骨折或> = 3次,分别在该人群中的可能性分别约为18%和21%。患者和提供者均可从对与同时阿片类药物和其他CNS-活跃的药物用途相关的不良反应意识中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号